

Karolinska Institutet, Stockholm

CHEMORES 2011
TUMOUR CHEMOTHERAPY RESISTANCE

September 21-22

Venue: Karolinska Hospital
(Karolinska Universitetssjukhuset Solna)
Dep. of Oncology and Pathology
Cancer Centrum Karolinska (CCK)
Building R8, 5th Floor
CCK R8 : 05
171 76 Stockholm

Workshop -the future of cancer therapy in the targeted therapy era

September 21, 2011 Wednesday

08.30-09.00 Registration and Coffee

09.00-09.10 Welcome By Johan Hansson (Karolinska Institutet, Sweden)

Session 1: How to understand and to reverse drug resistance
Chair: Rolf Lewensohn (Karolinska Institutet, Sweden)

09.10-09.50 **Parp Inhibitors sensitivity and resistance**
By Thomas Helleday (University of Oxford, UK)

09.50-10.10 **Functional genomic approaches to the dissection of drug resistance mechanisms in melanoma**
By Suzanne Egyhazi (Karolinska Institutet, Sweden)

10.10-10.30 **Functional genomic approaches to the dissection of drug resistance mechanisms in lung cancer**
By Luigi De Petris (Karolinska Institutet, Sweden)

10.30-11.00 Coffee Break

11.00-11.40 **Integration of system biology and bioinformatics in oncology**
By Stephen H. Friend (Sage Bionetworks, USA)

11.45-13.00 Lunch



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 21, 2011 Wednesday

Session 2: Towards the future: personalized medicine

Chair: Thomas Tursz (Institut Gustave Roussy, France)

13.00-13.30 Preliminary title: Overview and definition of biomarkers and predictive function

By Rolf Lewensohn (Karolinska Institutet, Sweden)

13.30-14.00 Is personalized medicine the future?

By Thomas Tursz (Institut Gustave Roussy, France)

14.00-14.30 How to personalize treatment in early lung cancer

By Benjamin Besse (Institut Gustave Roussy, France)

14.30-15.00 Limitations to individualized medicine

By Eytan Domany (Weizmann Institute of Science, Israel)

15.00-15.30 Coffee break

15.30-17.00 On-site seminars

Track I Clinical experiences: (Chair: Johan Hansson)

15.30-15.50 Patients sharing

15.50-16.05 Chemotherapy procedure

16.05-16.20 Case presentations by Luigi De Petris (KI, Sweden)

16.20-16.40 Case presentations by Gunnar Wagenius (Karolinska University Hospital, Sweden)

Track II Pre-clinical experiences: Life Science Lab

15.30-16.00 Janne Lehtiö (KI, Sweden)

16.00-16.30 Joakim Lundeberg (KTH, Sweden)

18.00

Dinner (Speakers only)



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 22, 2011 Thursday

Session 3: Melanoma therapy-realizing the potential in targeted therapy Chair: Johan Hansson (Karolinska Institutet, Sweden)

09.30-09.50 Registration and Coffee

09.50-10.30 **Recent advances in the treatment of advanced melanoma**
By Alexander M.M. Eggermont (Institut Gustave Roussy, France)

10.30-10.45 Coffee Break

10.45-11.20 **PLX 4032 and follow-up molecules**
By Mark Middleton (University of Oxford, UK)

11.20-11.55 **Role of pharmacokinetics in cancer chemotherapy**
By Curt Peterson (Linköping University, Sweden)

11.55-13.00 Lunch



**Karolinska
Institutet**

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Program

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

September 22, 2011 Thursday

Session 4: Current insights of biomarker assessment and clinical recommendations in lung cancer

13.00-13.30 Current status on lung cancer

By Rolf Stahel (University Hospital Zurich, Switzerland)

13.30-14.00 Novel targeted therapies for metastatic non-small cell lung cancer

By Rafal Dziadziuszko (Medical University of Gdansk, Poland)

14.00-14.30 Coffee break

14.30-16.30 Session 5: The future of cancer therapy?

Panel discussion

Moderator: Thierry le Chevalier (Institut Gustave Roussy, France)

Panelists:

- Nils Wilking (Karolinska Institutet, Sweden)
- Helena Brändström (Swedish National Board of Health and Welfare, Sweden)
- Representative from the Melanoma Association (Melanomföreningen, Sweden)
- Yvonne Brandberg (Cancerfonden & Karolinska Institutet, Sweden)
- Ulrik Ringborg (Karolinska University Hospital, Sweden)

16:30

Concluding remarks



**Karolinska
Institutet**

CHEMORRES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Thomas Helleday,
University of Oxford, UK

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

Professor Thomas Helleday was awarded a PhD from Stockholm University for his studies on homologous recombination in mammalian cells. After a short post-doctoral research period with Mark Meuth at the Institute for Cancer Research, Sheffield, UK, he obtained a lectureship at the same institute and set up his own group, with an interest in homologous recombination at replication forks in mammalian cells. At the same time, he maintained grants and a position at the Stockholm University, allowing his group to continue research at the Department of Genetics, Microbiology and Toxicology.

Many DNA damaging anti-cancer drugs cause replication-associated DNA damage that kill cancer cells. Homologous recombination is likely the most important repair pathway of replication-associated lesions and influences the clinical outcome of cancer therapies. The Helleday laboratories has focus the research into basic pathways for homologous recombination at replication forks and identifying novel anticancer therapies, ideally that exploit intrinsic genetic defects in the tumours, as is the case in BRCA1 and BRCA2 tumours.

Currently, Thomas Helleday is MRC Professor of Cancer Therapeutics at the Gray Institute for Radiation Oncology and Biology at the University of Oxford and Professor of Molecular Genetics at the Department of Genetics, Microbiology and Toxicology at Stockholm University. He has won numerous prestigious prizes including the Carcinogenesis Young Investigator Award 2010, the Swiss Bridge Award 2008 by Swiss Cancer League and the International Union Against Cancer (UICC), the Svedberg Award 2008 by SFBM and Swedish National Committee for Molecular Biosciences, the European Association for Cancer Research Young Cancer Researchers Award 2007, the Royal Swedish Academy of Sciences' Hilda and Alfred Eriksson's prize 2007 for an outstanding research contribution in relief of diseases in man or animal, British Association for Cancer Research (BACR) - AstraZeneca Young Scientist Frank Rose Award 2006, the Eppendorf-Nature Young European Investigator Award 2005 for outstanding contribution within the field of biomedical science and the European Environmental Mutagen Society (EEMS) Young Scientist Award 2005. The current focus in the Helleday laboratories is understanding and exploiting DNA repair and DNA-damage signalling pathways at replication forks for novel anti-cancer therapies .



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Suzanne Egyhazi,
Karolinska Institutet, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Egyhazi was awarded a PhD in Experimental Oncology from Karolinska Institutet for studies of resistance factors to DNA alkylating chloroethylnitrosourea drugs in malignant tumor cells.

Currently, her research is focused on identifying novel mechanisms of chemotherapy and targeted therapy resistance in cutaneous melanoma. The core studies of the project are based on analyses of already existing clinical samples, while *in vitro* models is used for functional validation of identified genes and exploratory studies of targeted therapeutic strategies.



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Luigi De Petris,
Karolinska Institutet, Sweden*September 21-22***Workshop -the future of cancer therapy in the targeted therapy era**

M.D. (University La Sapienza, Rome, Italy, 2000), Ph.D. (Karolinska Institutet, Stockholm, Sweden, 2010), post-graduate Specialization in Oncology (University La Sapienza, Rome, Italy, 2004). Main clinical and research focus: Lung Cancer. Member of European Society of Medical Oncology (ESMO), International Association for the Study of Lung Cancer (IASLC), Italian Association for Thoracic Oncology (AIOT).



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Stephen H. Friend,

Sage Bionetworks, USA

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Friend is the President of Sage Bionetworks. He was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck's Basic Cancer Research efforts. In 2005, he led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck's laboratories around the world, as well as to coordinate oncology programs from Basic Research through phase IIA clinical trials.

Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center's Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.



**Karolinska
Institutet**

Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Rolf Lewensohn,
Karolinska Institutet, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Rolf Lewensohn is the head of the Karolinska Biomic Centre and is at present a member of several research application evaluation committees. The research of Prof. Lewensohn focuses on the sensitivity of human tumors to radiation, as well as conventional and experimental chemotherapeutic drugs, with regard to the role of growth factor-, DNA-repair-, and apoptotic-signalling. Prof Lewensohn is also actively involved in drug development and is one of the founders of Oncopeptides AB Company, developing new anticancer drugs. He has also been involved in many clinical trials and is at present Vice Managing Director of the Clinical Cancer Trial Unit at Karolinska and is also managing several translational research projects in a joint venture between the Department of Oncology and KBC. He is adviser to several SME- and Big Pharma companies in the field of cancer drug development.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Thomas Tursz,
Institut Gustave Roussy, France

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Professor Thomas Tursz was Director General of the Institut Gustave Roussy from 1 October 1994 to 1 October 2010. He has held several key positions such as Internal Hôpitaux de Paris (1969), Chief of Clinic (1975), Professor of Oncology, Faculty of Medicine Paris-Sud (1986), Head of Oncology Department of Medicine at the Institut Gustave-Roussy (1986), Head of Department of Medicine, Institut Gustave-Roussy (1993).

Furthermore, he was the President of the National Federation of Centres for Combating Cancer (FNCLCC) since 2004, Director of the Doctoral School of Oncology Biology - Medicine - Health since 2000, Chairman of the Scientific Advisory Committee of the European Organization for Research and Treatment of Cancer (EORTC) (2003-2006), Vice Chairman of the EORTC (2006-2009), and President of the Organization of the European Cancer Institutes (OECI) 2002-2005.

He had a career in basic research and headed the Laboratory of Biology of Tumours of the IGR (UA 1156 CNRS) from 1984 to 1996. His research focused on virology and immunology of human tumors, particularly related to Epstein-Barr (EBV). He was President of the International Society for Research on the virus from 1994 to 1996.

Clinically, he is one of the pioneers in France of the use in new therapeutic cancer immunotherapy such as cytokines (interleukin 2, interferon). In his service began in 1994, the first gene therapy trial in lung cancer. He has received scientific awards, especially the price of Oncology French National League Against Cancer in 1979, the price of Immunology Bernard Halpern in 1983, the Rosen Prize for Cancer Research Foundation of Medical Research in 1989 Grand Prix of Oncology of the Academy of Medicine in 1992, Hamilton Fairley Award for Clinical Research in 1998, the Outreach Award French in 2001. He is Chevalier of the Legion of Honor since September 2001.

Dr. Tursz has authored 350 articles in national and international journals including Science, Nature, PNAS, JNCI, JCO, J. Biol. Chem., EMBO J., Lancet, Lancet Oncology, Brit Med J.



**Karolinska
 Institutet**

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Benjamin Besse,
Institut Gustave Roussy, France

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

Dr Benjamin Besse gained his medical oncology degree in 2005 from Paris University. Currently, Dr Besse is Head of the Thoracic Oncology Unit at the Institut Gustave Roussy. He holds a doctoral degree in translational research. He has launched the first molecular multidisciplinary staff dedicated to lung cancer patients in 2010 and is highly involved in clinical cancer research dedicated to lung cancer and new treatment strategy. He is member of the steering committees of IFCT, the French Intergroup for Lung Cancer Research.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Eytan Domany,

Weizmann Institute of Science, Israel

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Professor Domany received his PhD in Theoretical Physics in Cornell University, USA in 1977. He returned to Weizmann Institute of Science (WIS) as Senior Scientist in 1979 where he obtained his MSc in Theoretical Physics .

He received his professorship at WIS since 1986 and served as Head of the Dept. of Physics of Complex Systems between 1993- 1997 and of the The Kahn Family Center for Systems Biology of the Human Cell at the same institute since 2003. Since 2010 he serves also as Chairman of the Scientific Council. He is the incumbent of the Henry J Leir Professorial Chair. He held visiting professorships at various universities such as University of Oxford, Stanford University, the Ecole Normale Superieure and the Institut Curie.

The main research activity of his group is centered on trying to mine data from large-scale experiments in biology. The work ranges from development of mathematical methods, their implementation in algorithms, which are incorporated in user-friendly computational tools and these, finally, are applied to study biological data.

The main problem area studied by his group is that of cancer. The samples come mainly from various kinds of human tumors: of the colon, breast, brain, prostate, skin and leukemia. The aim is to uncover different molecular mechanisms that cause cancer, look for the underlying transcriptional networks and to correlate gene expression profiles with diagnosis, prognosis and, possibly, predict effective therapy. Considerable effort was devoted to attempts to describe genomic instabilities in cancer and their role in tumorigenesis. He also studies temporal variation of gene expression in cell lines that were subjected to some particular manipulation at some initial time (e.g. activation of p53, exposure IL6 or to EGF). Some more recent work focused on embryonic heart development and differentiation.



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

September 21-22

Gunnar Wagenius,
Karolinska University Hospital,
Sweden**Workshop -the future of cancer therapy in the targeted therapy era**

Dr. Gunnar Wagenius, Chief Physician and Associate Professor of Oncology at Karolinska University Hospital, and also serves at Radiumhemmet, Karolinska University Hospital Solna. Dr. Wagenius received his medical degree at Uppsala in 1984 and his PhD. in 1992 and has served as an oncologist almost 25 years. In daily practice, the focus is on lung cancer, esophageal cancer and malignant melanoma.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Janne Lehtiö,
Karolinska Institutet, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Lehtiö received his doctoral degree with title " Functional studies and engineering of family I carbohydrate binding modules" from Royal Institute of Technology (KTH) in 2001. He has been continued his postdoctoral work at Dept. Oncology-Pathology. His current positions are senior scientist, group leader, head of clinical proteomics core facility at Karolinska University Hospital, Platform manager/ Mass spectrometry at Science for Life Laboratory.

Before he joined KI, he also hold several previous positions such as: Research Scientist at CIPHERGEN Biosystems Inc. (San Francisco, USA and Copenhagen, Denmark), Technical research center of Finland (VTT, Espoo, Finland), Research assistant at University of Helsinki (ELISA development project), Research technician at Perkin Elmers (Wallac OY, Turku, Finland).

Dr. Lehtiö also received several awards including Young Scientist Award , Gordon conference, Boston, USA, 2001, Best Scientific Customer support Award, CIPHERGEN Biosystems, World Wide Meeting, CA, USA, 2003, Thought Leadership Award , Agilent Foundation, USA, 2009 –with motivation; future leader of translational omics research, world wide.

He is also the author of 35 original articles in refereed scientific journals, 6 Review articles and book chapters.



**Karolinska
Institutet**

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Joakim Lundeberg,
SciLifeLab, KTH, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Professor Joakim Lundeberg is the Head of Department, Gene Technology, KTH, Stockholm.

His research interest focuses on development and application of genetic technologies and bioinformatics tools for identification of gene/genome sequences, differentially expressed genes, single nucleotide polymorphisms, and identification of genetic alterations in pathological conditions. The aims with these technologies are to contribute to an improved understanding of gene function in the studied biological systems. In addition to technology development these tools are used in a series of ongoing collaborations covering both genetic analysis in metabolic and cancer disease, and transcriptome analysis in trees and stem cells niches. The development of new technologies include single transcriptome amplification technologies, single cell analysis, and methods to perform efficient massive parallel sequencing .

Dr. Lundeberg is also the Director of KTH Genome Center since 1998 and shared Director of Genomics platform at SciLifeLab, Stockholm.



CHEMORRES


TUMOUR CHEMOTHERAPY RESISTANCE

2011

Alexander Eggermont,
Institut Gustave Roussy, France

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Alexander M.M. Eggermont, MD, PhD is Full Professor of Surgical Oncology and Head of the Department of Surgical Oncology at the Erasmus University Medical Center – Daniel den Hoed Cancer Center in Rotterdam He is also Director of Institut Gustave Roussy, France. He holds the Chair of Experimental Surgical Oncology endowed by the Dutch Cancer Society and the “Joseph Maisin Chair” for Surgical Oncology at the Catholique University of Leuven in Belgium.

EORTC, FECS, ASCO, AACR, NCI and other International Functions

EORTC He is the immediate past President of the European Organization for Research and Treatment of Cancer (EORTC) He chairs the Steering Committee of the EORTC Network for Core Institutes (NOCI) and also chairs the Committee on Adjuvant Treatment Strategies of the EORTC-Melanoma Group.

FECS He is the current President-Elect of the Federation of European Cancer Societies (FECS)

ASCO He was elected to the 2005-2008 Board of Directors of ASCO (Surgical Oncology Seat). He serves as past chairman on the International Affairs committee of ASCO. Serves on JCO Editorial Board

AACR He serves on the AACR Centennial Committee, International affairs committee and the Tumor Immunology task Force. He is the current Deputy Editor of Clinical Cancer Research.

NCI: Serves on the NCI-CTEP advisory board.

Research

Clinical / Translational

He is specialized in treatment of Melanoma, Soft Tissue Sarcoma, molecular staging methods, and Regional Cancer Treatment Techniques such as isolated perfusion of extremities and organs. He has a special interest in adjuvant therapy and tumor immunology. He chairs the EORTC phase III adjuvant trial program in melanoma and is involved in various vaccination and other new drug phase I-II studies in melanoma.

Scientific output

He is author/coauthor of > 400 peer reviewed publications, book chapters and monographs.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Mark Middleton,
University of Oxford, UK

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Professor Mark Middleton is working on melanoma, the most serious form of skin cancer. He is based at the Churchill Hospital in Oxford where he is running several clinical trials testing new ways to treat the disease.

People with melanoma are often treated successfully with surgery, but unfortunately in some cases the cancer can come back. Professor Middleton is trying to crack the code of melanoma and identify 'molecular fingerprints' in blood and tumour samples that will predict if a patient's cancer is likely to return. This trial, called AVAST-M, is also investigating whether a drug called *bevacizumab* could help to reduce the risk of melanoma coming back after surgery, and identifying which patients could benefit from this treatment.

Professor Middleton's work will help us to understand which patients have a high risk of their cancer returning, and who will get the most benefit from *bevacizumab*. This research could lead to a new test enabling doctors to prescribe *bevacizumab* only to those patients whose cancer will respond, while sparing others from an unnecessary treatment. Work like this is bringing us a step closer to more personalised treatments for melanoma, helping to save even more lives.



CHEMORRES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Curt Peterson,
Linköping University, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

Professor Curt Peterson is supervisor for a number of graduate students in pharmacology chemotherapy, teaching in medical school. At the national level, he is head of the Clinical Trials Unit in oncology.

His main research interest is to individualize chemotherapy for cancer and chronic inflammatory diseases. Another interest is to improve the treatment of cytostatikainducerat nausea in cancer treatment.

Chemotherapy for cancer and inflammatory diseases is a difficult balance between the impact of the treatment, while avoiding severe side effects. Today is the treatment most often standardized to a certain number of mg per square meter of body surface area or kg of body weight. Genetic research has recently shown large variations in the activity of enzymes that metabolize drugs and carriers. We are working to identify the significance of such inherent variability of effects and side effects in order to be able to take them into account when the dosage of drugs to the patient so that the good effect is obtained without the risk of severe side effects.

One area he is studying is tiopurin and methotrexate therapy for childhood leukemia and tiopurinbehandling in inflammatory bowel disease and rheumatoid arthritis. For tiopuriner interest is mainly directed at the polymorphic enzyme thiopurine methyltransferase (TPMT) and inosine monophosphate dehydrogenase (IMPDH).

In cancer, he works primarily with ovarian cancer, lung cancer and various forms of leukemia, where the aim is that right from the start of therapy to determine the right dose of medicine based on the activities of a number of polymorphic enzymes and transport proteins.

He is Member of the Pharmaceutical Committee and chairman of the regional expert group to assess cancer drugs, Deputy member of the Ethics Committee.



CHEMORRES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

September 21-22

Rolf Stahel,
University/Hospital of Zurich,
Switzerland

Workshop -the future of cancer therapy in the targeted therapy era



Rolf A. Stahel, M.D. is Senior Staff Physician at the Clinic and Policlinic of Oncology, University Hospital of Zürich and Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research and targeted therapy.

He was a founding member and the first president of the Swiss Society for Medical Oncology. He served as president of the Swiss Institute for Applied Cancer Research from 1999 to 2005. He is member of the International Association for the Study of Lung Cancer (IASLC), where he served as chair of the fellowship committee and since 2009 is a member of the board of directors. In the European Society for Medical Oncology (ESMO) he served as National Representative from 1998 to 2004 and chaired ESMO Task Force on Guidelines from 1999 to 2005. Since 2003 he is member of the ESMO board of directors and since 2006 he is the chair of the ESMO Educational Committee and member of the ESMO Executive Committee. In addition, he is president-elect of ESMO (2012).

Since 2008 he is president of the foundation council of the International Breast Cancer Study Group (IBCSG). Since 2009 he is president of the European Thoracic Oncology Platform (ETOP), a foundation with the aim to bring together European collaborative groups and institutions focusing on research on thoracic malignancies.

He is editor in-chief of Lung Cancer and editor of Cancer Treatment Reviews.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

September 21-22

Rafal Dziadziuszko,

Medical University of Gdansk, Poland

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Rafal Dziadziuszko completed his training in Radiotherapy (2001) and Medical Oncology (2004) at the Department of Oncology and Radiotherapy of Medical University of Gdansk, Poland.

He subsequently completed translational cancer research fellowship at the University of Colorado Cancer Center. Between 2005 and 2007 he worked on predictive assays for EGFR targeted therapies in lung cancer, including immunohistochemistry, gene copy number and activating mutations. He then returned to his home institution to serve as a deputy chair of the department.

Dr. Dziadziuszko's main interests include lung cancer and clinical research methodology, and he is a co-author of several peer-reviewed articles and book chapters on this matter. He is a member of European Organization for Research and Treatment of Cancer – Lung Cancer and Radiotherapy Groups, European Society of Medical Oncology, American Society of Clinical Oncology and American Association for Cancer Research. He has also participated in organization of numerous academic clinical research studies in Poland and Central Europe through Polish Lung Cancer Group and serves as the Vice-Chairman of the Central and East European Oncology Group.

His current work includes identification of novel targets for lung cancer trials and early lung cancer detection. He has been involved in IGF1R and MET translational and clinical research.



Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Thierry Le Chevalier,
Institut Gustave Roussy, France

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Professor Thierry le Chevalier, M.D. is the Head of Department of Medicine in Institut Gustave-Roussy (France).



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Nils Wilking,**Karolinska Institutet, Sweden***September 21-22***Workshop -the future of cancer therapy in the targeted therapy era**

Nils Wilking MD PhD has been active in clinical oncology for 30 years after graduating from the Karolinska Institutet in Stockholm, Sweden. He has worked for many years in the field of surgical oncology, but has since the late 1980s mainly worked with medical oncology and then with a focus on breast and GI cancer. He headed the breast and GI cancer unit at the Karolinska hospital during 1992-1998. During this period he also set up and headed the clinical trial unit at the department of oncology.

In 1998 he joined Eli Lilly as a senior research physician. In 2001 he moved to BMS where he held a European position in their oncology team. Since 2003 he has worked with research linked to the Karolinska Institutet. He now, since 2010, also serves as Senior Strategic Advisor for the Southern Health Care Region in Sweden.

His main focus has been on research in relation to health service delivery. This work, in collaboration with Professor Bengt Jönsson at the Stockholm School of Economics, has resulted in a number of reports with a focus on patient's access to cancer therapy. These reports include information on more than 55 countries. See link below.

www.comparatorreports.se

**Karolinska
Institutet**

Karolinska Institutet, Stockholm

CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

September 21-22

Helena Brändström,
Swedish National Board of Health and
Welfare, Sweden

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Helena Brändström works as a coordinator of cancer issues at the Swedish National Board of Health and Welfare and is the project leader of national guidelines for breast, colorectal and prostate cancer.



CHEMORES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Yvonne Brandberg,
Karolinska Institutet, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era

Dr. Yvonne Brandberg is Professor of Care Sciences with focus on oncology at the Department of Oncology-Pathology since 2007.

The research consists for the most part of preventative studies and quality of life assessment in malignant melanoma and breast cancer.

Within the framework of an EU project, information is compiled about the sun exposure habits of the general public compared to patients with malignant melanoma.

Another project focuses on the psychological consequences of prophylactic mastectomy in women with an inherited risk of developing breast cancer. In addition, psychological problems following brachytherapy and hormone treatment in patients with prostate cancer are being studied.

She is also a scientific secretariat at Swedish Cancer Society (Cancerfonden).



CHEMORRES

TUMOUR CHEMOTHERAPY RESISTANCE

2011

Ulrik Ringborg,
Karolinska University Hospital, Sweden

September 21-22

Workshop -the future of cancer therapy in the targeted therapy era



Dr. Ulrik Ringborg completed his Doctoral thesis at the Karolinska Institute (Sweden) in 1971 on *Nucleolar RNA Synthesis, processing and transport in salivary gland cells of Chironomus tentans*, and was appointed as Associate Professor of Histology that same year. He received his Med. Lic. Degree and State registration as medical practitioner in 1972.

He became Associate Professor of General Oncology in 1978, qualifying as an oncology specialist in 1979 and, in 1987 was Consultant at the Department of General Oncology, Radiumhemmet. In 1992 he accepted appointments as Senior Consultant, Department of General Oncology, Radiumhemmet, Professor of Oncology, Karolinska Institute, and Head of the Department of Oncology, Karolinska Hospital.

From 1993-96 he was Prefect at the Institute of Oncology-Pathology and since 1994 he has been Director of the Cancer Center Karolinska. From 1995-2003 he was Head, the Division of Oncology at the Karolinska Hospital and in 1996 he served as Member of the Executive Group of the Karolinska Hospital until 2003. The following year, he headed the Oncologic Clinic of the new Karolinska University Hospital until 2005.

Ulrik Ringborg is currently Senior Physician, Professor of Oncology, and Director of the Cancer Center Karolinska. As Director, he coordinates the formation of a Comprehensive Cancer Center of all cancer activities at the Karolinska University Hospital and the Karolinska Institute. He has published over 273 papers in international journals and books on malignant melanoma.

He has served as Member on countless Boards and Assemblies including the Research Boards/Governing Bodies of the Stockholm Cancer Society, the King Gustaf V Jubilee Fund, the Nobel Assembly, the Swedish Cancer Society. Dr. Ulrik Ringborg is also Member of the Scientific Advisory Committee of EORTC and the Steering Group of NOCI, EORTC.

He is Past-President of the Organisation of European Cancer Institutes (OEI), Chairman of the Advisory Board for UV-protection, Swedish Radiation Protection Authority, Honorary Member of the Radiological Society of North America and Board Member of ECCO – the European Cancer Organisation.

